Recon: Makary reportedly sought CRL for KalVista drug; Novo launches Wegovy in India

• FDA's Makary sought rejection of KalVista’s drug in an unusual move by commissioner, sources say (Endpoints)
• A grim milestone: U.S. is on the cusp of losing its official measles elimination status (STAT)
• Cassidy calls to delay meeting of CDC’s vaccine panel in challenge to RFK Jr. (STAT)
• Capricor says US FDA may not convene expert panel for co's cell therapy (Reuters)
• US health secretary Kennedy says he brought back 722 CDC employees, 220 at NIH (Reuters)
• Crosstalk On Drug Pricing: Conflicts In Trump Team Rhetoric And Policy (Pink Sheet)
• US CDC report shows no link between thimerosal-containing vaccines and autism (Reuters)
• Cigna sues Bristol Myers for alleged monopoly over blockbuster cancer drug (Reuters)

• Novo Nordisk launches weight-loss drug Wegovy in India to compete with Lilly's Mounjaro (Reuters)
• Gates Foundation to commit $1.6 billion for Gavi vaccine alliance (Reuters)
• EU Sees Unified Pathway For Drug/IVD Studies As Key To Future Research Investment (Pink Sheet)
• New Drug Procurement Rules Aim To Drive Pharma Investment In Mexico (Pink Sheet)
• UK government blueprints ambition to be a key life sciences hub  (Endpoints)
• £2Bn Industrial Strategy Boost For UK Life Sciences Growth Sector (MedTech Insight)
• Home-Testing Added To UK National Cervical Cancer Screening Program (MedTech Insight)
• Amarin sells Vascepa's rights in Europe to Recordati for $25M (Fierce Pharma)

• Nuvalent says its ROS1-targeted drug shrank lung tumors in patients who failed other options (STAT)
• GLP-1 drug helped type 1 diabetes patients keep healthy glucose levels and lose weight (STAT)
• Amgen’s obesity drug led to high discontinuation rates in mid-stage trial, as company plans to adjust dosing (STAT)
• Nektar's mid-stage eczema data deliver key win in bid for company turnaround (Endpoints)
• ArriVent plots next steps for lung cancer drug; Neuron23's $96.5M raise (Endpoints)
• AstraZeneca, Daiichi Sankyo gain lung cancer indication for Enhertu successor (Endpoints)
• Roche plans to pit next-gen hemophilia A antibody against Hemlibra in Phase 3 (Endpoints)
• Exelixis' positive Phase 3 colorectal cancer data boost stock (Endpoints)
• Royalty Pharma to pay up to $2 billion to Revolution Medicines for cancer drug (Reuters)
• Craig Romanok takes up chief commercial officer post at Digitas (Fierce Pharma)

• Device that uses biodegradable polymers to repair peripheral nerves gets FDA clearance (STAT)
• From boom to bitcoin: A device maker’s surprising pivot amid a Medicare crackdown (STAT)
• Why this health tech investor thinks AI could bring the ‘learning health system’ to life (STAT)
• Illumina to buy SomaLogic for up to $425M (MedTech Dive)
• ADA takeaways: Diabetes tech firms preview new patch pumps, glucose sensors (MedTech Dive)
• GE Healthcare recalls Carestation devices over ventilation failure risk (MedTech Dive)
• New Openwater Data Shows Promise For AI-Driven Optical Rapid Stroke Detection (MedTech Insight)

• Texas Governor Abbott Signs MAHA-Similar Bill into Law (Food Safety)
• David responds to lawsuit, denies hoarding ingredient (Food Business News)

• US health secretary Kennedy says he brought back 722 CDC employees, 220 at NIH (Reuters)
• Health insurers promise to reduce barriers to care under pressure from Trump administration (STAT)
• The Senate’s version of Trump’s tax-cut bill threatens safety-net hospitals like ours (STAT)
• Balkanization of vaccine policy raises concerns about vaccine uptake, insurance coverage, experts warn (STAT)
• Supreme Court asks DOJ to weigh in on Hikma ‘skinny label’ fight against (Endpoints)